Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides

Journal of Proteome Research

Volumn 13, Issue 11, 2014, Pages 5250-5261

  Genovese, Filippo ^a   Gualandi, Alessandra ^a   Taddia, Laura ^a   Marverti, Gaetano ^a   Pirondi, Silvia ^a   Marraccini, Chiara ^a   Perco, Paul ^b   Pelà, Michela ^c   Guerrini, Remo ^c   Amoroso, Maria Rosaria ^a   Esposito, Franca ^d   Martello, Andrea ^a   Ponterini, Glauco ^a   D'Arca, Domenico ^a   Costi, Maria Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Emergentec Biodevelopment GmbH   (Austria)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

anticancer drugs; bioinformatics; drug targets; folate pathway; human thymidylate synthase peptidic inhibitors; label free quantification; ovarian cancer; pemetrexed

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG ANALOG; LR PEPTIDE; OCTAPEPTIDE; PEMETREXED; PROTEIN; PROTEOME; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; [DEXTRO GLN 4]LR PEPTIDE; ANTINEOPLASTIC ANTIMETABOLITE; FOLIC ACID; GLUTAMIC ACID DERIVATIVE; GUANINE; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CANCER RESISTANCE; CELL ACTIVITY; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MULTIDRUG RESISTANCE; OVARIAN CANCER CELL LINE; PEPTIDE ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; MASS SPECTROMETRY; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PEPTIDES; PROTEINS; REPRODUCIBILITY OF RESULTS; THYMIDYLATE SYNTHASE;

EID: 84908871369     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500510v     Document Type: Article

References (53)

1. Altman, R. B.; Rubin, D. L.; Klein, T. E. An Omics View of Drug Development Drug Dev. Res. 2004, 62, 81-85
2. Collinson, F.; Hutchinson, M.; Craven, R. A.; Cairn, D. A.; Zougman, A.; Tobias, C.; Wind, N. G.; Messenger, M. P.; Jackson, S.; Thompson, D.; Aduseis, C.; Ledermann, J. A.; Hall, G.; Jayson, G. C.; Selby, P. J.; Banks, R. E. Predicting response to bevacizumab in ovarian cancer: A panel of potential biomarkers informing treatment selection Clin. Cancer Res. 2013, 19, 5227-5239
3. Zahedi, P.; Yoganathan, R.; Piquette-Miller, M.; Allen, C. Recent advances in drug delivery strategies for treatment of ovarian cancer Expert Opin. Drug Delivery 2012, 9, 567-583
4. Han, B.; Stockwin, L. H.; Hancock, C.; Yu, S. X.; Hollingshead, M. G.; Newton, D. L. Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor J. Proteome Res. 2010, 9, 4016-4027
5. Rahman, L.; Voeller, D.; Rahman, M.; Lipkowitz, S.; Allegra, C.; Barrett, J. C.; Kaye, F. J.; Zajac-Kaye, M. Thymidylate synthase as an oncogene Cancer Cell 2004, 5, 341-351
6. Lehman, N. L. Future potential of thymidylate synthase inhibitors in cancer therapy Expert Opin. Investig. Drugs 2002, 11, 1775-1787
7. Pullarkat, S. T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y.-P.; Ingles, S. A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S.; Lenz, H.-J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy Pharmacogenomics J. 2001, 1, 65-70
8. Scanlon, K. J.; Kashani-Sabet, M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 650-653
9. Marverti, G.; Ligabue, A.; Paglietti, G.; Corona, P.; Piras, S.; Vitale, G.; Guerrieri, D.; Luciani, R.; Costi, M. P.; Frassineti, C.; Moruzzi, M. S. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells Eur. J. Pharmacol. 2009, 615, 17-26
10. Miller, R. E.; Banerjee, S. The current state of pemetrexed in ovarian cancer Expert Opin. Investig. Drugs 2013, 22, 1201-10
11. Cardinale, D.; Guaitoli, G.; Tondi, D.; Luciani, R.; Henrich, S.; Salo-Ahen, O. M. H.; Ferrari, S.; Marverti, G.; Guerrieri, D.; Ligabue, A.; Frassineti, C.; Pozzi, C.; Mangani, S.; Fessas, D.; Guerrini, R.; Ponterini, G.; Wade, R. C.; Costi, M. P. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 2011, 108, E542-E549
12. Pelà, M.; Saxena, P.; Luciani, R.; Santucci, M.; Ferrari, S.; Marverti, G.; Marraccini, C.; Martello, A.; Pirondi, S.; Genovese, F.; Salvadori, S.; Drassi, D.; Ponterini, G.; Costi, M. P.; Guerrini, R. Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth J. Med. Chem. 2014, 57, 1355-1367
13. Pils, D.; Tong, D.; Hager, G.; Obermayr, E.; Aust, S.; Heinze, G.; Kohl, M.; Schuster, E.; Wolf, A.; Sehouli, J.; Braicu, I.; Vergote, I.; Van Gorp, T.; Mahner, S.; Concin, N.; Speiser, P.; Zeillinger, R. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancera study of the OVCAD consortium BMC Cancer 2013, 13 178
14. Wis̈niewski, J. R.; Ostasiewicz, P.; Dus̈, K.; Zielińska, D. F.; Gnad, F.; Mann, M. Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma Mol. Syst. Biol. 2012, 8, 611
15. Benoiton, N. L. Chemistry of Peptide Synthesis; Taylor&Francis: London, U.K., 2005; pp 125-154.
16. Chambers, M. C. A cross-platform toolkit for mass spectrometry and proteomics Nat. Biotechnol. 2012, 30, 918-920
17. Edwards, N.; Wu, X.; Tseng, C.-W. An Unsupervised, Model-Free, Machine-Learning Combiner for Peptide Identifications from Tandem Mass Spectra Clin. Proteomics 2009, 5, 23-36
18. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry Anal. Chem. 2003, 75, 4646-4658
19. Tsou, C.-C.; Tsai, C.-F.; Tsui, Y.-H.; Sudhir, P.-R.; Wang, Y.-T.; Chen, Y.-J.; Chen, J.-Y.; Sung, T.-Y.; Hsu, W.-L. IDEAL-Q, an Automated Tool for Label-free Quantitation Analysis Using an Efficient Peptide Alignment Approach and Spectral Data Validation Mol. Cell. Proteomics 2010, 9, 131-144
20. Taverner, T.; Karpievitch, Y. V.; Polpitiya, A. D.; Brown, J. N.; Dabney, A. R.; Anderson, G. A.; Smith, R. D. DanteR: An extensible R-based tool for quantitative analysis of-omics data Bioinformatics 2012, 28, 2404-2406
21. Bernthaler, A.; Mpievitch, I.; Fechete, R.; Perco, P.; Lukas, A.; Mayer, B. A dependency graph approach for the analysis of differential gene expression profiles Mol. BioSyst. 2009, 5, 1720-1731
22. Heinzel, A.; Fechete, R.; I, S.; Fechete, R.; Perco, P.; Lukas, A.; Mayer, B.; Aayer, G.; Lukas, A.; Mayer, B. Data graphs for linking clinical phenotype and molecular feature space Int. J. Syst. Biol. Biomed. Technol. 2012, 1, 11-25
23. Fechete, R.; Heinzel, A.; Söllner, J.; Perco, P.; Lukas, A.; Mayer, B. Using information content for expanding human protein coding gene interaction networks J. Comput. Sci. Syst. Biol. 2013, 6, 73-82
24. Bader, G. D.; Hogue, C. W. V. An automated method for finding molecular complexes in large protein interaction networks BMC Bioinf. 2003, 4 2
25. Croft, D.; OKelly, G.; Wu, G.; Haw, R.; Gillespie, M.; Matthews, L.; Caudy, M.; Garapati, P.; Gopinath, G.; Jassal, B.; Jupe, S.; Kalatskaya, I.; Mahajan, S.; May, B.; Ndegwa, N.; Schmidt, E.; Shamovsky, V.; Yung, C.; Birney, E.; Hermjakob, H.; DEustachio, P.; Stein, L. Reactome: A database of reactions, pathways and biological processes Nucleic Acids Res. 2011, 39, D691-D697
26. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A comprehensive resource for Omics research on drugs Nucleic Acids Res. 2011, 39, D1035-D1041
27. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 1970, 227, 680-685
28. Li, C.; Wong, W. H. DNA-Chip Analyzer (dChip). The analysis of gene expression data. Statistics for Biology and Health; Springer: New York, 2003; pp 120-141.
29. Saiki, Y.; Yoshino, Y.; Fujimura, H.; Manabe, T.; Kudo, Y.; Shimada, M.; Mano, N.; Nakano, T.; Lee, Y.; Shimizu, S.; Oba, S.; Fujiwara, S.; Shimizu, H.; Chen, N.; Nezhad, Z. K.; Jin, G.; Fukushige, S.; Sunamura, M.; Ishida, M.; Motoi, F.; Egawa, S.; Unno, M.; Horii, A. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells Biochem. Biophys. Res. Commun. 2012, 421, 98-104
30. Landriscina, M.; Amoroso, M. R.; Piscazzi, A.; Esposito, F. Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy Gynecol. Oncol. 2010, 117, 177-182
31. Taipale, M.; Jarosz, D. F.; Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell. Biol. 2010, 11, 515-528
32. Mahalingam, D.; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting HSP90 for cancer therapy Br. J. Cancer. 2009, 100, 1523-1529
33. de Haro, C.; M; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting HSP9 FASEB J. 1996, 10, 1378-1387
34. Nazki, F. H.; Sameer, A. S.; Ganaie, B. A. Folate: Metabolism, genes, polymorphisms and the associated diseases Gene 2014, 533, 11-20
35. Key, M. A tutorial in displaying mass spectrometry-based proteomic data using heat maps BMC Bioinf. 2012, 13 S10
36. Lu, X.; Errington, J.; Curtin, N. J.; Lunec, J.; Newell, D. R. The Impact of p53 Status on Cellular Sensitivity to Antifolate Drugs Clin. Cancer Res. 2001, 7, 2114-2123
37. Wilson, P. M.; LaBonte, M. J.; Lenz, H. J.; Mack, P. C.; Ladner, R. D. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer Mol. Cancer Ther. 2011, 11, 616-628
38. Perry, W. L.; Shepard, R. L.; Sampath, J. Human Splicing Factor SPF45 (RBM17) Confers Broad Multidrug Resistance to Anticancer Drugs When Overexpressed-a Phenotype Partially Reversed By Selective Estrogen Receptor Modulators Cancer Res. 2005, 65, 6593-6600
39. Loizeau, K.; De Brouwer, V.; Gambonnet, B.; Yu, A.; Renou, J.-P-; Van Der Straeten, D.; Lambert, W. E.; Rébeillé, F.; Ravanel, S. A genome-wide and metabolic analysis determined the adaptive response of arabidopsis cells to folate depletion induced by methotrexate Plant Physiol. 2008, 148, 2083-2095
40. Walker, G.; MacLeod, K.; Williams, A. R.; Cameron, D. A.; Smyth, J. F.; Langdon, S. P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer Gynecol. Oncol. 2007, 106, 461-468
41. Matassa, D. S.; Amoroso, M. R.; Maddalena, F.; Landriscina, M.; Esposito, F. New insights into TRAP1 pathway Am. J. Cancer Res. 2012, 2, 235-248
42. Kang, B. H.; Plescia, J.; Dohi, T.; Rosa, J.; Doxsey, S. J.; Altieri, D. C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network Cell 2007, 131, 257-270
43. Bazzaro, M.; Lee, M. K.; Zoso, A.; Stirling, W. L. H.; Santillan, A.; Shih, I.-M.; Roden, R. B. S. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis Cancer Res. 2006, 66, 3754-3763
44. Altieri, D. C.; Stein, G. S.; Lian, J. B.; Languino, L. R. TRAP1, the mitochondrial Hsp90 Biochim. Biophys. Acta 2012, 1823, 767-773
45. Mahalingham, D.; Swords, R.; Carew, J. S.; Nawrocki, S. T.; Bhalla, K.; Giles, F. J. Targeting HSP90 for cancer therapy Br. J. Cancer 2009, 100, 1523-1529
46. French, J. B.; Zhao, H.; An, S.; Niessen, S.; Deng, Y.; Cravatt, B. F.; Benkovic, S. J. Hsp70/Hsp90 chaperone machinery is involved in the assembly of the purinosome Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2528-2533
47. Siegelin, M. D.; Plescia, J.; Raskett, C. M.; Gilbert, C. A.; Ross, A. H.; Altieri, D. C. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma Mol. Cancer Ther. 2010, 9, 1638-1646
48. Ewing, R. M. Large scale mapping of human protein-protein interactions by mass spectrometry Mol. Syst. Biol. 2007, 3, 89
49. Dressman, H. K.; Berchuck, A.; Chan, G.; Zhai, J.; Bild, A.; Sayer, R.; Cragun, J.; Clarke, J.; Whitaker, R. S.; Li, L.; Gray, J.; Marks, J.; Ginsburg, G. S.; Potti, A.; West, M.; Nevins, J. R.; Lancaster, J. M. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J. Clin. Oncol. 2007, 25, 517-525
50. Liu, Y.-C-; Li, F.; Handler, J.; Huang, C. R. L.; Xiang, Y.; Neretti, N.; Sedivy, J. M.; Zeller, K. I.; Dang, C. V. Global regulation of nucleotide biosynthetic genes by c-myc PLoS One 2008, 3 e27222
51. Boccalatte, F. E.; Voena, C.; Riganti, C.; Bosia, A.; DAmico, L.; Riera, L.; Cheng, M.; Ruggeri, B.; Jensen, O. N.; Goss, V. L.; Lee, K.; Nardone, J.; Rush, J.; Polakiewicz, R. D.; Comb, M. J.; Chiarle, R.; Inghirami, G. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL Blood 2009, 113, 2776-2790
52. Richardson, P. G.; Mitsiades, C.; Hideshima, T.; Anderson, K. C. Bortezomib: proteasome inhibition as an effective anticancer therapy Annu. Rev. Med. 2006, 57, 33-47
53. García, M. A.; Carrasco, E.; Aguilera, M.; Alvarez, P.; Rivas, C.; Campos, J. M.; Prados, J. C.; Calleja, M. A.; Esteban, M.; Marchal, J. A.; Aránega, A. The chemotherapeutic drug 5-fluorouracil promotes pkr-mediated apoptosis in a p53-independent manner in colon and breast cancer cells PLoS One 2011, 6 e23887